WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection ...

A live webcast of the presentation can be accessed on the investor relations section of the Intensity Therapeutics website. A replay of the webcast will be archived and available following the event ...

INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology ...

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of ...

Investors might want to bet on Intensity Therapeutics Inc. (INTS Quick Quote INTS - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward ...

) has been revised to $57.29 / share. This is a decrease of 11.32% from the prior estimate of $64.60 dated March 25, 2026. The price target is an average of many targets provided by analysts. The ...

The Connective Tissue Oncology Society was formed in 1995 and incorporated in 1997. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of ...

Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday. Check out the current price of INTS stock here. Shares of the biotechnology company rallied 394.9% in Thursday's regular ...

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the ...

Intensity Therapeutics (NASDAQ:INTS) just reported results for the second quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly ...

Intensity Therapeutics Inc. (INTS Quick Quote INTS - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of ...